Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H23F3N6O |
InChIKeyMVCJEDLGJGHLJM-UHFFFAOYSA-N |
CAS Registry2098211-50-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | IT | 02 Jul 2024 |